At a glance
ClinicalIndex Comparison RecordN/ACompleted· 65 enrolled
Drug / intervention
XIENCE PRIME SV EECSSdevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
SPIRIT PRIME JAPAN (SV JAPAN)
In Brief
A clinical study evaluating XIENCE PRIME SV EECSS for Vascular Disease and 5 related conditions. Completed, enrolled 65 participants across 14 sites.
Detailed Summary
The purpose of this study is to evaluate the safety and effectiveness of the AVJ-09-385 Small Vessel Everolimus Eluting Coronary Stent System (EECSS) (2.25 mm diameter stent) in treatment of subjects with ischemic heart disease caused by de novo lesions.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsVascular Disease, Myocardial Ischemia, Coronary Artery Stenosis, Coronary Disease, Coronary Artery Disease, Coronary Restenosis
CountriesJapan
Collaborators--
Timeline
N/ACompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartApr 2010
First PostedMay 2010
Primary CompletionAug 2011
Study CompletionDec 2013
TodayJul 2026
First PostedMay 4, 2010
Enrollment StartApr 1, 2010
Primary CompletionAug 1, 2011
Study CompletionDec 1, 2013
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 16.2 years ago
Interventions
XIENCE PRIME SV EECSSdevice
Patients receiving XIENCE PRIME SV EECSS